Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

KRAS inhibitor

- PMLiVE

AZ buoyed by latest lung cancer data at ESMO

Data from separate Tagrisso and Imfinzi trials show superior PFS among patients

- PMLiVE

Amgen signs real world study and mobile data partnership

Will work with health and wellbeing group Humana on risk prevention

- PMLiVE

Biocon backs away from biosimilar filings in Europe

EMA asks biotech to withdraw Herceptin and Neulasta biosimilar filings

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

- PMLiVE

Race to CGRP migraine drug finish line enters the final straight

US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab

- PMLiVE

FDA rejects Amgen’s osteoporosis hope romosozumab

Its partner UCB plans to submit the medicine for European approval later this year

- PMLiVE

Amgen aspires to new Kyprolis label in the US and Europe

Appeals to regulators to add survival data to multiple myeloma drug's labelling

- PMLiVE

FDA panel backs Avastin and Herceptin biosimilars

A decision from the US regulator is expected in September

Novartis building

Novartis’ Zykadia claims US approval for first-line lung cancer

The Swiss pharma giant’s drug also receives CHMP positive opinion

AstraZeneca AZ

AZ buoyed by Imfinzi lung cancer trial

Phase III study shows PD-L1 inhibitor increased progression-free survival

- PMLiVE

Merck gains ground in lung cancer with first-line combo approval

Keytruda wins FDA backing for all first-line NSCLC patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links